

Prior Authorization DRUG Guidelines

Descovy
(tenofovir alafenamide and emtricitabine)

Effective Date 01/24/2017

Developed 12/01/2016 by R. Sterling, MD

Date Approved by P&T Committee: 1/24/17, 1/23/18, 1/22/19, 2/18/20

ARCHIVED 3/16/2020

DESCOVY is a fixed dose combination tablet containing emtricitabine (FTC) 200 mg and tenofovir alafenamide (TAF) 25 mg. FTC, a synthetic nucleoside analog of cytidine, is an HIV nucleoside analog reverse transcriptase inhibitor (HIV NRTI). TAF, an HIV NRTI, is converted *in vivo* to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine_5'-monophosphate.

Note:

VCHCP requires that Combivir be prescribed by an Immunology Clinic physician with current American Academy of HIV Medicine (AAHIVM) certification or a physician boarded in Infectious Disease.

Pre-authorization Criteria: HIV-1 infection (in combination with other antiretroviral agents) in adults and pediatric patients 12 years of age and older

NOTE: not indicated for post-exposure prophylaxis; not approved for chronic hepatitis B infection

Dosing: one tablet daily, with or without food

Dosage Forms: combination tablet emtricitabine 200 mg and tenofovir alafenamide 25 mg

Adverse Reactions/Precautions: Black Box Warnings: may exacerbate hepatitis B infection in HIV patients; fatal lactic acidosis with steatosis has been reported; nausea and vomiting; decreased bone mineral density; immune reconstitution syndrome (reactivation of inflammatory response to latent infection); renal toxicity (caution using NSAIDs);

Drug Interactions: use caution with NSAIDs (renal toxicity); may increase serum concentration: acyclovir, valacyclovir; may decrease serum concentration: phenytoin, fosphenytoin, carbamazepine, phenobarbital, rifampin

REFERENCES:

Descovy (emtricitabine and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences; April 2016.

Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors

Tenofovir Alafenamide (Genvoya, Odefsey, Descovy, TAF). <https://aidsinfo.nih.gov/guidelines>; 2016

Revision History:

Date Developed: 12/01/16 by R. Sterling, MD

Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD

Date Approved by P&T Committee: 1/24/17

Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD

Date Approved by P&T Committee: 1/23/18

Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/22/19

Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/18/20

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
2/18/20	No	Howard Taekman, MD; Robert Sterling, MD	Annual review